Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is JPMorgan Chase & Co. (NYSE:JPM) Going to Burn These Hedge Funds?

There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each year by hiring the best and the brightest to do research on stocks, including small cap stocks that big brokerage houses simply don’t cover. Because of Carl Icahn and other elite funds’ exemplary historical records, we pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze JPMorgan Chase & Co. (NYSE:JPM), a large-cap stock that has been delivering small-cap stock returns.

JPMorgan Chase & Co. (NYSE:JPM) was in 92 hedge funds’ portfolios at the end of June. JPM investors should pay attention to a decrease in enthusiasm from smart money of late. There were 100 hedge funds in our database with JPM positions at the end of the previous quarter. Nevertheless, JPM is still the 14th most popular stock among hedge funds at the end of the second quarter (see the list of 25 most popular stocks among hedge funds).

In the 21st century investor’s toolkit there are many indicators market participants can use to evaluate publicly traded companies. A pair of the most useful indicators are hedge fund and insider trading moves. We have shown that, historically, those who follow the top picks of the best hedge fund managers can outperform their index-focused peers by a superb margin. Insider Monkey’s flagship best performing hedge funds strategy returned 17.4% year to date and outperformed the market by more than 14 percentage points this year. This strategy also outperformed the market by 3 percentage points in the fourth quarter despite the market volatility (see the details here).


Boykin Curry of Eagle Capital

Let’s take a gander at the latest hedge fund action regarding JPMorgan Chase & Co. (NYSE:JPM).

What does the smart money think about JPMorgan Chase & Co. (NYSE:JPM)?

At Q3’s end, a total of 92 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -8% from the second quarter of 2018. The graph below displays the number of hedge funds with bullish position in JPM over the last 6 quarters. So, let’s find out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.


More specifically, Lansdowne Partners was the largest shareholder of JPMorgan Chase & Co. (NYSE:JPM), with a stake worth $1340.7 millions reported as of the end of June. Trailing Lansdowne Partners was Eagle Capital Management, which amassed a stake valued at $643.7 millions. Greenhaven Associates, Brave Warrior Capital, and Argentiere Capital were also very fond of the stock, giving the stock large weights in their portfolios.

Judging by the fact that JPMorgan Chase & Co. (NYSE:JPM) has witnessed bearish sentiment from the entirety of the hedge funds we track, it’s safe to say that there lies a certain “tier” of hedge funds who sold off their full holdings last quarter. Interestingly, Aaron Cowen’s Suvretta Capital Management sold off the biggest investment of the “upper crust” of funds followed by Insider Monkey, valued at close to $135.4 million in stock. Scott Bessent’s fund, Key Square Capital Management, also cut its stock, about $65.2 million worth. These moves are intriguing to say the least, as total hedge fund interest fell by 8 funds last quarter.

Let’s now review hedge fund activity in other stocks – not necessarily in the same industry as JPMorgan Chase & Co. (NYSE:JPM) but similarly valued. We will take a look at Exxon Mobil Corporation (NYSE:XOM), Johnson & Johnson (NYSE:JNJ), Royal Dutch Shell plc (ADR) (NYSE:RDS), and Visa Inc (NYSE:V). This group of stocks’ market valuations are closest to JPM’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
XOM 50 2222523 -7
JNJ 66 5711736 -2
RDS 39 2329498 3
V 109 13035656 -7

As you can see these stocks had an average of 66 hedge funds with bullish positions and the average amount invested in these stocks was $5825 million. That figure was $7011 million in JPM’s case. Visa Inc (NYSE:V) is the most popular stock in this table. On the other hand Royal Dutch Shell plc (ADR) (NYSE:RDS) is the least popular one with only 39 bullish hedge fund positions. JPMorgan Chase & Co. (NYSE:JPM) is not the most popular stock in this group but hedge fund interest is still above average. We are in an increasing interest rate environment and historically financial stocks do better in this environment. That’s why we expect financial stocks like Visa and JP Morgan to outperform the S&P 500 Index that is now dominated by overpriced technology stocks that are likely to underperform as cost of capital creeps up.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.